NEOPLASMS BY SITE
Clinical trials for NEOPLASMS BY SITE explained in plain language.
Never miss a new study
Get alerted when new NEOPLASMS BY SITE trials appear
Sign up with your email to follow new studies for NEOPLASMS BY SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…
Matched conditions: NEOPLASMS BY SITE
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New hope for rare lung cancer: taletrectinib made available outside clinical trials
Disease control NO_LONGER_AVAILABLEThis program offers taletrectinib, an experimental drug, to adults with advanced or spreading ROS1-positive non-small cell lung cancer who cannot join a current clinical trial or use approved treatments. Participants must have a confirmed ROS1 gene fusion and adequate organ funct…
Matched conditions: NEOPLASMS BY SITE
Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
New pill targets Hard-to-Treat cancers with AKT1 mutation
Disease control OngoingThis early-stage study tests an experimental pill, ATV-1601, in adults with advanced solid tumors or certain breast cancers that have a specific AKT1 gene change. The main goals are to find a safe dose and check how the drug moves through the body. About 134 participants will tak…
Matched conditions: NEOPLASMS BY SITE
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New combo therapy shows promise for common lung cancer mutation
Disease control OngoingThis study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…
Matched conditions: NEOPLASMS BY SITE
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Robotic surgery or radiation? new study compares which is better for throat cancer patients' quality of life
Symptom relief OngoingThis study compares two treatments for early-stage throat cancer: robotic surgery (TORS) or radiation therapy (IMRT). It looks at which one leads to better swallowing function and overall quality of life. About 138 adults with HPV-related throat cancer are taking part. The goal i…
Matched conditions: NEOPLASMS BY SITE
Phase: NA • Sponsor: Christian von Buchwald • Aim: Symptom relief
Last updated May 27, 2026 23:06 UTC
-
Robot-Assisted lung biopsy under the microscope: will it deliver?
Knowledge-focused OngoingThis study is tracking over 1,300 people who are having a lung biopsy or lesion localization with the Ion Endoluminal System, a robotic device. The goal is to see how often the device successfully gets a diagnosis and how often complications like a collapsed lung or bleeding occu…
Matched conditions: NEOPLASMS BY SITE
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:58 UTC
-
Can doctor training boost lung cancer care in smaller cities?
Knowledge-focused OngoingThis study looks at whether educating doctors in small and mid-sized city hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted treat…
Matched conditions: NEOPLASMS BY SITE
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:10 UTC